Biotech Analysts discuss Rhythm Pharmaceuticals’ (RYTM) Setmelanotide for the opportunity to treat acquired hypothalamic obesity on an Analyst/Industry conference call to be held on July 14 .
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $119 from $94 at Guggenheim
- Rhythm Pharmaceuticals price target raised to $110 from $76 at Oppenheimer
- Rhythm Pharmaceuticals 2.059M share Spot Secondary priced at $85.00
- Rhythm Pharmaceuticals prices 2.06M shares at $85.00 in upsized public offering
- Rhythm Pharmaceuticals price target raised to $129 from $91 at Wells Fargo